Melanoma
From the Journals
Vaccine regimen boosts immune response in malignant melanoma
Adding a hematopoietic cytokine to a dendritic cell-targeted vaccine improved responses.
Conference Coverage
Mitotic rate makes comeback as melanoma prognosticator
Key insight: the relationship between mitotic rate and melanoma survival is nonlinear.
Conference Coverage
Risk factors for severe immune-related AEs identified
A nationwide cohort study of more than 14,000 patients finds combination immune checkpoint inhibitor therapy, younger age, and a lung cancer...
Conference Coverage
Low threshold to biopsy atypical lesions may ID vulvar melanoma early, experts say
To diagnose one melanoma, doctors may need to biopsy many lesions.
Conference Coverage
What happened to melanoma care during COVID-19 sequestration
Preliminary evidence indicates delayed diagnosis and treatment measurably worsened outcome indicators.
Tips
Intraoperative Tissue Expansion to Allow Primary Linear Closure of 2 Large Adjacent Surgical Defects
It is becoming increasingly more common for dermatology patients to present for treatment of multiple skin cancers during the same appointment....
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
From the Journals
Survey of Mohs surgeons highlights its use in invasive melanoma
“Mohs surgeons who previously treated MIS with MMS may be increasingly doing so and/or expanding their scope of treatment to include invasive...
Conference Coverage
Lenvatinib combo may offer hope after immunotherapy in melanoma
From the Journals
Durable response 5 years after adjuvant combo in melanoma
Plateaus observed with relapse and distant metastasis-free survival suggest that true disease cures are being achieved with treatment.
From the Journals
Fatal pediatric melanomas diverse in presentation
One-fourth of fatal pediatric melanomas arose in association with congenital melanocytic nevi.